ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration

FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet